Prognostic implications of ferroptosis-associated gene signature in colon adenocarcinoma

Table 1 Clinicopathological features of the colon adenocarcinoma patients in two databases, n (%)

	TCGA-COAD	GSE39582
Number of patients	385	566
Survival status
Alive	306 (79.5)	371 (65.5)
Dead	79 (20.5)	191 (33.7)
Unknown		4 (0.8)
Survival time in d
Range for OS days	0-4502	0-2412
OS days, median	670	612
Age in yr	67.00 ± 12.76	66.87 ± 13.28
Range	31-90	22-97
Median	69	68
Sex
Female	180 (46.7)	256 (45.2)
Male	205 (53.2)	310 (54.8)
Stage
I	66 (17.1)	33 (5.8)
II	151 (39.2)	264 (46.6)
III	103 (26.8)	205 (36.2)
IV	54 (14.0)	60 (10.6)

TCGA-COAD: The Cancer Genome Atlas database-colon adenocarcinoma; OS: Overall survival.

Table 2 Baseline features of the colon adenocarcinoma patients in different risk groups, n (%)

Features	TCGA-COAD cohort			GEO-GSE39582 cohort
	High-risk	Low-risk	P value	High-risk	Low-risk	P value
Age			0.795			0.862
< 65 yr	70 (39.5)	68 (38.2)		105 (37.4)	107 (38.1)
≥ 65 yr	107 (60.5)	110 (61.8)		176 (62.6)	174 (61.9)
Sex			0.265			0.351
Female	86 (48.6)	76 (42.7)		132 (47.0)	121 (43.1)
Male	91 (51.4)	102 (57.3)		149 (53.0)	160 (56.9)
TNM-stage			P < 0.001			P = 0.002
I and II	83 (46.9)	114 (64.0)		134 (47.7)	170 (60.5)
III and IV	89 (50.3)	58 (32.6)		145 (51.6)	109 (38.8)
Unknown	5 (2.8)	6 (3.4)		2 (0.7%)	2 (0.7%)

TCGA-COAD: The Cancer Genome Atlas database-colon adenocarcinoma; GEO: Gene Expression Omnibus.